SPI Infoamtion

本レポートに関しましてはExecutive Summaryのみ 195USD での販売も行っておりますので、
お問い合わせ下さい。

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF CHARTS

EXECUTIVE SUMMARY
1.1 U.S. MARKET FOR DIABETES DIAGNOSIS, TREATMENT AND DRUG DELIVERY
1.2 TREND ANALYSIS BY SEGMENT
1.3 BLOOD GLUCOSE MONITORING MARKET
1.4 DIABETIC POPULATION
1.5 INSULIN
1.6 INSULIN SYRINGES
1.7 INSULIN PENS
1.8 INSULIN PUMPS
1.9 ORAL ANTIDIABETIC DRUGS
1.9.1 Price Analysis
1.9.2 Market Analysis
1.10 LEADING COMPETITORS IN THE DIABETES DEVICES MARKET
1.11 LEADING COMPETITORS IN THE INSULIN AND ANTIDIABETIC DRUG MARKET

RESEARCH METHODOLOGY
2.1 RESEARCH SCOPE
2.2 IDATA'S 9-STEP METHODOLOGY
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecast and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring

OVERVIEW OF DIABETES
3.1 INTRODUCTION
3.2 MAIN TYPES OF DIABETES
3.2.1 Type 1 Diabetes
3.2.2 Type 2 Diabetes
3.2.3 Gestational Diabetes
3.2.4 Prediabetes
3.3 DIABETES COMPLICATIONS
3.4 RISK FACTORS ASSOCIATED WITH TYPE 1 AND TYPE 2 DIABETES
3.5 SIGNS AND SYMPTOMS
3.6 MONITORING
3.6.1 Initial Diagnosis
3.6.2 Blood Glucose Monitoring Systems
3.6.3 Urinary Glucose Monitoring
3.6.4 Noninvasive and Minimally Invasive Monitoring Devices
3.7 TREATMENT
3.7.1 Lifestyle Measures
3.7.2 Insulin
3.7.3 Oral Antidiabetic Drugs
3.7.4 Injectable Antidiabetic Drugs
3.8 DRUG DELIVERY
3.8.1 Insulin Syringes
3.8.2 Insulin Pens
3.8.3 Insulin Pumps
3.8.4 Inhaled Insulin
3.8.5 Insulin Patches
3.9 EMERGING TECHNOLOGIES
3.10 MARKET OVERVIEW
3.11 MARKET ANALYSIS BY SEGMENT
3.12 TREND ANALYSIS AND FORECAST BY SEGMENT
3.13 MARKET DRIVERS AND LIMITERS
3.13.1 Market Drivers
3.13.2 Market Limiters
3.14 COMPETITIVE ANALYSIS

DIABETES IN THE U.S
4.1 DIABETES PREVALENCE
4.2 DIABETES INCIDENCE
4.3 DIABETES DEMOGRAPHICS
4.4 OBESITY PREVALENCE

TRADITIONAL BLOOD GLUCOSE METERS
5.1 INTRODUCTION
5.2 MARKET ANALYSIS AND FORECAST
5.2.1 Total Blood Glucose Monitoring Market
5.2.2 Total Traditional Blood Glucose Meter Market
5.2.3 Professional Traditional Blood Glucose Meter Market
5.2.4 Personal Traditional Blood Glucose Meter Market
5.3 MARKET DRIVERS AND LIMITERS
5.3.1 Market Drivers
5.3.2 Market Limiters
5.4 COMPETITIVE ANALYSIS

CONTINUOUS GLUCOSE MONITORING SYSTEMS
6.1 INTRODUCTION
6.2 MARKET ANALYSIS AND FORECAST
6.2.1 Total Blood Glucose Monitoring Market
6.2.2 Continuous Glucose Monitoring System Market
6.3 MARKET DRIVERS AND LIMITERS
6.3.1 Market Drivers
6.3.2 Market Limiters
6.4 COMPETITIVE ANALYSIS

BLOOD GLUCOSE TEST STRIPS
7.1 INTRODUCTION
7.2 MARKET ANALYSIS AND FORECAST
7.2.1 Total Blood Glucose Monitoring Market
7.2.2 Diabetic Population Using Blood Glucose Monitor Test Strips
7.2.3 Total Blood Glucose Test Strip Market
7.2.4 Professional Blood Glucose Test Strip Market
7.2.5 Personal Blood Glucose Test Strip Market
7.3 MARKET DRIVERS AND LIMITERS
7.3.1 Market Drivers
7.3.2 Market Limiters
7.4 COMPETITIVE ANALYSIS

LANCETS AND LANCING DEVICES
8.1 INTRODUCTION
8.2 MARKET ANALYSIS AND FORECAST
8.2.1 Total Blood Glucose Monitoring Market
8.2.2 Total Lancet and Lancing Device Market
8.2.3 Professional Lancet and Lancing Device Market
8.2.4 Personal Lancet and Lancing Device Market
8.3 MARKET DRIVERS AND LIMITERS
8.3.1 Market Drivers
8.3.2 Market Limiters
8.4 COMPETITIVE ANALYSIS

INSULIN
9.1 INTRODUCTION
9.1.1 Insulin Types
9.2 MARKET ANALYSIS AND FORECAST
9.2.1 Total Insulin Market
9.2.2 Rapid-Acting Insulin Analogs
9.2.3 Regular and Intermediate-Acting Human Insulin
9.2.4 Long-Acting Insulin Analog
9.2.5 Insulin Mixtures
9.3 MARKET DRIVERS AND LIMITERS
9.3.1 Market Drivers
9.3.2 Market Limiters
9.4 COMPETITIVE ANALYSIS

INSULIN SYRINGES
10.1 INTRODUCTION
10.2 MARKET ANALYSIS AND FORECAST
10.2.1 Total Insulin Syringe Market
10.2.2 Professional Insulin Syringe Market
10.2.3 Personal Insulin Syringe Market
10.3 MARKET DRIVERS AND LIMITERS
10.3.1 Market Drivers
10.3.2 Market Limiters
10.4 COMPETITIVE ANALYSIS

INSULIN PENS
11.1 INTRODUCTION
11.2 MARKET ANALYSIS AND FORECAST
11.3 MARKET DRIVERS AND LIMITERS
11.3.1 Market Drivers
11.3.2 Market Limiters
11.4 COMPETITIVE ANALYSIS

INSULIN PUMPS
12.1 INTRODUCTION
12.2 MARKET ANALYSIS AND FORECAST
12.2.1 Total Insulin Pump and Insulin Pump Infusion Set Market
12.2.2 Insulin Pump Market
12.2.3 Insulin Pump Infusion Set Market
12.3 MARKET DRIVERS AND LIMITERS
12.3.1 Market Drivers
12.3.2 Market Limiters
12.4 COMPETITIVE ANALYSIS

ORAL ANTIDIABETIC DRUGS
13.1 INTRODUCTION
13.2 MARKET ANALYSIS AND FORECAST
13.2.1 Total Oral Antidiabetic Drug Market
13.2.1.1 Unit Analysis
13.2.1.2 Price Analysis
13.2.1.3 Market Analysis
13.2.2 Alpha-Glucosidase Inhibitors
13.2.3 Biguanides
13.2.3.1 Total Biguanide Market
13.2.3.2 Brand Name Biguanide Market
13.2.3.3 Generic Biguanide Market
13.2.4 DPP-IV Inhibitors
13.2.5 Sulfonylureas
13.2.5.1 Total Sulfonylurea Market
13.2.5.2 Brand Name Sulfonylurea Market
13.2.5.3 Generic Sulfonylurea Market
13.2.6 Meglitinides
13.2.7 Thiazolidinediones
13.2.8 Single Pill Combinations
13.3 MARKET DRIVERS AND LIMITERS
13.3.1 Market Drivers
13.3.2 Market Limiters
13.4 COMPETITIVE ANALYSIS

INJECTABLE ANTIDIABETIC DRUGS
14.1 INTRODUCTION
14.2 MARKET ANALYSIS AND FORECAST
14.2.1 Total Injectable Antidiabetic Drug Market
14.2.1.1 Unit Analysis
14.2.1.2 Price Analysis
14.2.1.3 Market Analysis
14.2.2 GLP-1 Receptor Agonists
14.2.3 Amylinomimetics
14.3 MARKET DRIVERS AND LIMITERS
14.3.1 Market Drivers
14.3.2 Market Limiters
14.4 COMPETITIVE ANALYSIS

ABBREVIATIONS

LIST OF FIGURES

EXECUTIVE SUMMARY

RESEARCH METHODOLOGY

OVERVIEW OF DIABETES
Figure 3-1: Major Types of Diabetes and Related Pathologies
Figure 3-2: Risk Factors Associated with Type 1 and Type 2 Diabetes
Figure 3-3: Signs and Symptoms Associated with Type 1 and Type 2 Diabetes
Figure 3-4: Blood Glucose Ranges Recommended by the American Diabetes Association (ADA), U.S., 2009
Figure 3-5: Total Diabetes Diagnosis, Treatment and Drug Delivery Market by Segment, U.S., 2006 - 2016
Figure 3-6: Trend Analysis, Growth Rates by Market Segment, U.S. Market for Diabetics Diagnosis, Treatment and Drug Delivery, 2006 - 2016
Figure 3-7: Drivers and Limiters in the U.S. Market for Diabetes Diagnosis, Treatment and Drug Delivery, 2009
Figure 3-8: Leading Competitors in the Diabetes Diagnosis, Monitoring, Treatment and Drug Delivery Market, U.S., 2006 - 2016 (Part 1)
Figure 3-9: Leading Competitors in the Diabetes Diagnosis, Monitoring, Treatment and Drug Delivery Market, U.S., 2006 - 2016 (Part 2)
Figure 3-10: Leading Competitors in the Devices Segment of the Total Market for Diabetes Diagnosis, Treatment and Drug Delivery, U.S., 2009
Figure 3-11: Leading Competitors in the Insulin and Antidiabetic Drug Segment of the Total Market for Diabetes Diagnosis, Treatment and Drug Delivery, U.S., 2009

DIABETES IN THE U.S
Figure 4-1: Total Prevalence of Diabetes Both Diagnosed and Undiagnosed, Adults Aged 18 - 79, U.S., 2006 - 2016
Figure 4-2: Incidence of Diabetes in Adults Aged 18 - 79, U.S., 2006 - 2016
Figure 4-3: Percentage of Population Diagnosed with Diabetes by Race and Sex, U.S., 2006 - 2016
Figure 4-4: Obesity Prevalence in Adults by State, Alabama to Mississippi, U.S., 2008 (Part 1)
Figure 4-5: Obesity Prevalence in Adults by State, Missouri to Wyoming, U.S., 2008 (Part 2)

TRADITIONAL BLOOD GLUCOSE METERS
Figure 5-1: Blood Glucose Ranges Recommended by the American Diabetes Association (ADA), U.S., 2009
Figure 5-2: Total Blood Glucose Monitoring Market, U.S., 2006 - 2016
Figure 5-3: Total Traditional Blood Glucose Meter Market by Segment, U.S., 2006 - 2016
Figure 5-4: Professional Traditional Blood Glucose Meter Market, U.S., 2006 - 2016
Figure 5-5: Personal Traditional Blood Glucose Meter Market, U.S., 2006 - 2016
Figure 5-6: Drivers and Limiters, Traditional Blood Glucose Meter Market, U.S., 2009
Figure 5-7: Leading Competitors in the Traditional Blood Glucose Meter Market, U.S., 2009

CONTINUOUS GLUCOSE MONITORING SYSTEMS
Figure 6-1: Total Blood Glucose Monitoring Market, U.S., 2006 - 2016
Figure 6-2: Continuous Glucose Monitoring System Market, U.S., 2006 - 2016
Figure 6-3: Drivers and Limiters, Continuous Glucose Monitoring System Market, U.S., 2009
Figure 6-4: Leading Competitors in the Continuous Glucose Monitoring System Market, U.S., 2009

BLOOD GLUCOSE TEST STRIPS
Figure 7-1: Total Blood Glucose Monitoring Market, U.S., 2006 - 2016
Figure 7-2: Diabetic Population Using Blood Glucose Monitor Test Strips, U.S., 2006 - 2016
Figure 7-3: Total Blood Glucose Test Strip Market by Segment, U.S., 2006 - 2016
Figure 7-4: Professional Blood Glucose Test Strip Market by Segment, U.S., 2006 - 2016
Figure 7-5: Personal Blood Glucose Test Strip Market by Segment, U.S., 2006 - 2016
Figure 7-6: Drivers and Limiters, Blood Glucose Test Strips Market, U.S., 2009
Figure 7-7: Leading Competitors in the Blood Glucose Test Strips Market, U.S., 2009

LANCETS AND LANCING DEVICES
Figure 8-1: Total Blood Glucose Monitoring Market, U.S., 2006 - 2016
Figure 8-2: Total Market for Lancets and Lancing Devices by Segment, U.S., 2006 - 2016
Figure 8-3: Professional Market for Lancets and Lancing Devices, U.S., 2006 - 2016
Figure 8-4: Personal Market for Lancets and Lancing Devices, U.S., 2006 - 2016
Figure 8-5: Drivers and Limiters, Lancet and Lancing Device Market, U.S., 2009
Figure 8-6: Leading Competitors in the Lancet and Lancing Device Market, U.S., 2009

INSULIN
Figure 9-1: Onset, Peak and Duration of Insulin Types, U.S., 2009
Figure 9-2: Brand Name Insulin, U.S., 2009
Figure 9-3: Total Market for Insulin by Segment, U.S., 2006 - 2016
Figure 9-4: Rapid-Acting Insulin Analog Market, U.S., 2006 - 2016
Figure 9-5: Regular and Intermediate-Acting Human Insulin Market, U.S., 2006 - 2016
Figure 9-6: Long-Acting Insulin Analog Market, U.S., 2006 - 2016
Figure 9-7: Insulin Mixture Market, U.S., 2006 - 2016
Figure 9-8: Drivers and Limiters for the Insulin Market, U.S., 2009
Figure 9-9: Leading Competitors in the Insulin Market, U.S., 2009

INSULIN SYRINGES
Figure 10-1: Total Market for Insulin Syringes by Segment, U.S., 2006 - 2016
Figure 10-2: Professional Market for Insulin Syringes, U.S., 2006 - 2016
Figure 10-3: Personal Market for Insulin Syringes, U.S., 2006 - 2016
Figure 10-4: Drivers and Limiters for the Insulin Syringe Market, U.S., 2009
Figure 10-5: Leading Competitors in the Total Insulin Syringe Market, U.S., 2009

INSULIN PENS
Figure 11-1: Insulin Pens Market, U.S., 2006 - 2016
Figure 11-2: Drivers and Limiters for the Insulin Pen Market, U.S., 2009
Figure 11-3: Leading Competitors in the Insulin Pen Market, U.S., 2009

INSULIN PUMPS
Figure 12-1: Total Market for Insulin Pumps and Insulin Pump Infusion Sets by Segment, U.S., 2006 - 2016
Figure 12-2: Insulin Pump Market, U.S., 2006 - 2016
Figure 12-3: Insulin Pump Infusion Set Market, U.S., 2006 - 2016
Figure 12-4: Drivers and Limiters for the Insulin Pump Market, U.S., 2009
Figure 12-5: Leading Competitors in the Insulin Pump Market, U.S., 2009

ORAL ANTIDIABETIC DRUGS
Figure 13-1: Oral Antidiabetic Drug Overviews, U.S., 2009
Figure 13-2: Oral Antidiabetic Drug Indications, U.S., 2009 (Part 1)
Figure 13-3: Oral Antidiabetic Drug Indications, U.S., 2009 (Part 2)
Figure 13-4: Oral Antidiabetic Drug Indications, U.S., 2009 (Part 3)
Figure 13-5: Oral Antidiabetic Drugs, U.S., 2009 (Part 1)
Figure 13-6: Oral Antidiabetic Drugs, U.S., 2009 (Part 2)
Figure 13-7: Adult Doses of Oral Antidiabetic Drugs, U.S., 2009 (Part 1)
Figure 13-8: Adult Doses of Oral Antidiabetic Drugs, U.S., 2009 (Part 2)
Figure 13-9: Oral Antidiabetic Drugs FDA Approval and Patent Expiry, U.S., 2009 (Part 1)
Figure 13-10: Oral Antidiabetic Drug Units, U.S., 2009
Figure 13-11: Oral Antidiabetic Drug Price Indices, U.S., 2009
Figure 13-12: Total Oral Antidiabetic Drug Market by Segment, U.S., 2006 - 2016
Figure 13-13: Alpha-Glucosidase Inhibitor Market, U.S., 2006 - 2016
Figure 13-14: Total Biguanide Market by Segment, U.S., 2006 - 2016
Figure 13-15: Brand-Name Biguanide Market, U.S., 2006 - 2016
Figure 13-16: Generic Biguanide Market, U.S., 2006 - 2016
Figure 13-17: DPP-IV Inhibitor Market, U.S., 2006 - 2016
Figure 13-18: Total Sulfonylurea Market by Segment, U.S., 2006 - 2016
Figure 13-19: Brand-Name Sulfonylurea Market, U.S., 2006 - 2016
Figure 13-20: Generic Sulfonylurea Market, U.S., 2006 - 2016
Figure 13-21: Meglitinide Market, U.S., 2006 - 2016
Figure 13-22: Thiazolidinedione (TZD) Market, U.S., 2006 - 2016
Figure 13-23: Single Pill Combination Market, U.S., 2006 - 2016
Figure 13-24: Drivers and Limiters for the Oral Antidiabetic Drug Market, U.S., 2009
Figure 13-25: Leading Competitors in the Oral Antidiabetic Drug Market, U.S., 2009

INJECTABLE ANTIDIABETIC DRUGS
Figure 14-1: Injectable Antidiabetic Drug Indications, U.S., 2009
Figure 14-2: Injectable Antidiabetic Drugs, U.S., 2009
Figure 14-3: Injectable Antidiabetic Drugs, U.S., 2009
Figure 14-4: Injectable Antidiabetic Drugs, FDA Approval and Patent Expiry, U.S., 2009
Figure 14-5: Injectable Antidiabetic Drug Units, U.S., 2009
Figure 14-6: Injectable Antidiabetic Drug Price Indices, U.S., 2009
Figure 14-7: Total Injectable Antidiabetic Drug Market by Segment, U.S., 2006 - 2016
Figure 14-8: GLP-1 Receptor Agonist Market, U.S., 2006 - 2016
Figure 14-9: Amylinomimetic Market, U.S., 2006 - 2016
Figure 14-10: Drivers and Limiters for the Injectable Antidiabetic Drug Market, U.S., 2009
Figure 14-11: Leading Competitors in the Injectable Antidiabetic Drug Market, U.S., 2009

ABBREVIATIONS

LIST OF CHARTS

EXECUTIVE SUMMARY
Chart 1-1: Market for Diabetes Diagnosis, Treatment and Drug Delivery, U.S., 2006 - 2016
Chart 1-2: Fastest Growing Market Segments, Diabetes Diagnosis, Treatment and Drug Delivery Market, U.S., 2006 - 2016
Chart 1-3 : Blood Glucose Test Strips as a Proportion of the Total Blood Glucose Monitoring Market, U.S., 2009
Chart 1-4: Prevalence of Diabetes Both Diagnosed and Undiagnosed, Adults Aged 18 - 79, U.S., 2006 - 2016
Chart 1-5: Average Onset, Peak and Duration of Insulin Types Used in the U.S., 2009
Chart 1-6: Total Market for Insulin Syringes by Segment, U.S., 2006 - 2016
Chart 1-7: Insulin Pump Market by Segment, U.S., 2006 - 2016
Chart 1-8: Price Index Comparison, Oral Antidiabetic Drugs, U.S., 2009
Chart 1-9: Market Growth Analysis, Oral Antidiabetic Drugs, U.S., 2009
Chart 1-10: Leading Competitors in the Combined Market for Diabetes Devices, U.S., 2009
Chart 1-11: Leading Competitors in the Combined Market for Insulin and Antidiabetic Drugs, U.S., 2009

RESEARCH METHODOLOGY

OVERVIEW OF DIABETES
Chart 3-1: Total Diabetes Diagnosis, Treatment and Drug Delivery Market, U.S., 2006 - 2016
Chart 3-2: Total Diabetes Diagnosis, Monitoring, Treatment and Drug Delivery Market by Segment, U.S., 2009
Chart 3-3: Total Diabetes Diagnosis, Monitoring, Treatment and Drug Delivery Market by Segment, U.S., 2016
Chart 3-4: Fastest Growing Market Segments, Diabetes Diagnosis, Treatment and Drug Delivery Market, U.S., 2006 - 2016
Chart 3-5: Leading Competitors in the Total Diabetes Diagnosis, Monitoring, Treatment and Drug Delivery Market, U.S., 2006 - 2016
Chart 3-6: Leading Competitors in the Devices Segment of the Total Market for Diabetes Diagnosis, Treatment and Drug Delivery, U.S., 2009
Chart 3-7: Leading Competitors in the Insulin and Antidiabetic Drug Segment of the Total Market for Diabetes Diagnosis, Treatment and Drug Delivery, U.S., 2009

DIABETES IN THE U.S
Chart 4-1: Prevalence of Diabetes Both Diagnosed and Undiagnosed, Adults Aged 18 - 79, U.S., 2006 - 2016
Chart 4-2: Incidence of Diabetes in Adults Aged 18 - 79, U.S., 2006 - 2016
Chart 4-3: Percentage of Population Diagnosed with Diabetes by Race and Sex, U.S., 2009
Chart 4-4: Obesity Prevalence in Adults by State, U.S., 2008

TRADITIONAL BLOOD GLUCOSE METERS
Chart 5-1: Traditional Blood Glucose Monitors as a Proportion of the Total Blood Glucose Monitoring Market, U.S., 2009
Chart 5-2: Total Traditional Blood Glucose Meter Market by Segment, U.S., 2006 - 2016
Chart 5-3: Professional Traditional Blood Glucose Meter Market, U.S., 2006 - 2016
Chart 5-4: Personal Traditional Blood Glucose Meter Market Segmented by= Price Range, U.S., 2009
Chart 5-5: Personal Traditional Blood Glucose Meter Market, U.S., 2006 - 2016
Chart 5-6: Leading Competitors in the Blood Glucose Monitoring Device Market, U.S., 2009

CONTINUOUS GLUCOSE MONITORING SYSTEMS
Chart 6-1: Continuous Glucose Monitoring Systems as a Proportion of the Total Blood Glucose Monitoring Market, U.S., 2009
Chart 6-2: Continuous Glucose Monitoring System Market, U.S., 2006 - 2016
Chart 6-3: Leading Competitors in the Continuous Glucose Monitoring System Market, U.S., 2009

BLOOD GLUCOSE TEST STRIPS
Chart 7-1: Blood Glucose Test Strips as a Proportion of the Total Blood Glucose Monitoring Market, U.S., 2009
Chart 7-2: Total Blood Glucose Test Strip Market by Segment, U.S., 2006 - 2016
Chart 7-3: Professional Blood Glucose Test Strip Market by Segment, U.S., 2006 - 2016
Chart 7-4: Personal Blood Glucose Test Strip Market by Segment, U.S., 2006 - 2016
Chart 7-5: Leading Competitors in the Blood Glucose Test Strips Market, U.S., 2009

LANCETS AND LANCING DEVICES
Chart 8-1: Lancets and Lancing Devices as a Proportion of the Total Blood Glucose Monitoring Market, U.S., 2009
Chart 8-2: Total Market for Lancets and Lancing Devices by Segment, U.S., 2006 - 2016
Chart 8-3: Professional Market for Lancets and Lancing Devices, U.S., 2006 - 2016
Chart 8-4: Personal Market for Lancets and Lancing Devices, U.S., 2006 - 2016
Chart 8-5: Leading Competitors in the Lancet and Lancing Device Market, U.S., 2009

INSULIN
Chart 9-1: Onset, Peak and Duration of Insulin Types, U.S., 2009
Chart 9-2: Total Market for Insulin by Segment, U.S., 2006 - 2016
Chart 9-3: Rapid-Acting Insulin Analog Market, U.S., 2006 - 2016
Chart 9-4: Regular and Intermediate-Acting Human Insulin Market, U.S., 2006 - 2016
Chart 9-5: Long-Acting Insulin Analog Market, U.S., 2006 - 2016
Chart 9-6: Insulin Mixture Market, U.S., 2006 - 2016
Chart 9-7: Leading Competitors in the Insulin Market, U.S., 2009

INSULIN SYRINGES
Chart 10-1: Total Market for Insulin Syringes by Segment, U.S., 2006 - 2016
Chart 10-2: Professional Market for Insulin Syringes, U.S., 2006 - 2016
Chart 10-3: Personal Market for Insulin Syringes, U.S., 2006 - 2016
Chart 10-4: Leading Competitors in the Total Insulin Syringe Market, U.S., 2009

INSULIN PENS
Chart 11-1: Insulin Pen Market, U.S., 2006 - 2016
Chart 11-2: Leading Competitors in the Insulin Pen Market, U.S., 2009

INSULIN PUMPS
Chart 12-1: Total Market for Insulin Pumps and Insulin Pump Infusion Sets by Segment, U.S., 2006 - 2016
Chart 12-2: Insulin Pump Market, U.S., 2006 - 2016
Chart 12-3: Insulin Pump Infusion Set Market, U.S., 2006 - 2016
Chart 12-4: Leading Competitors in the Insulin Pump Market, U.S., 2009

ORAL ANTIDIABETIC DRUGS
Chart 13-1: Total Oral Antidiabetic Drug Market by Segment, U.S., 2006 - 2016
Chart 13-2: Total Oral Antidiabetic Drug Market by Segment, U.S., 2009
Chart 13-3: Alpha-Glucosidase Inhibitor Market, U.S., 2006 - 2016
Chart 13-4: Total Biguanide Market by Segment, U.S., 2006 - 2016
Chart 13-5: Brand Name Biguanide Market, U.S., 2006 - 2016
Chart 13-6: Generic Biguanide Market, U.S., 2006 - 2016
Chart 13-7: DPP-IV Inhibitor Market, U.S., 2006 - 2016
Chart 13-8: Total Sulfonylurea Market by Segment, U.S., 2006 - 2016
Chart 13-9: Brand Name Sulfonylurea Market, U.S., 2006 - 2016
Chart 13-10: Generic Sulfonylurea Market, U.S., 2006 - 2016
Chart 13-11: Meglitinide Market, U.S., 2006 - 2016
Chart 13-12: Thiazolidinedione (TZD) Market, U.S., 2006 - 2016
Chart 13-13: Single Pill Combination Market, U.S., 2006 - 2016
Chart 13-14: Leading Competitors in the Oral Antidiabetic Drug Market, U.S., 2009

INJECTABLE ANTIDIABETIC DRUGS
Chart 14-1: Total Injectable Antidiabetic Drug Market by Segment, U.S., 2006 - 2016
Chart 14-2: Total Injectable Antidiabetic Drug Market by Segment, U.S., 2009
Chart 14-3: GLP-1 Receptor Agonist Market, U.S., 2006 - 2016
Chart 14-4: Amylinomimetic Market, U.S., 2006 - 2016
Chart 14-5: Leading Competitors in the Injectable Antidiabetic Drug Market, U.S., 2009

ABBREVIATIONS